Big Pharma Lukewarm To License Compounds From Indian Start-ups, But A Few Could Be Head Turners
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Faced with the bleak prospect of an almost irreversible pipeline drought, Big Pharma has sharpened its focus on identifying differentiated leads from smaller firms - mainly to in-license early-stage compounds - but it appears there are few Indian start-ups with compounds that fit into this strategic goal